Table 1.

Cohort 1 (N=131): Clinical Characteristics and Maintenance Medication in the Past at Entry into the GAN Registry, ie, Before Starting Mepolizumab Therapy

Baseline characteristics (N=131*)
Exacerbations during the past 12 months	n	%
Never	4	3.1
1× peryear	10	7.6
>1× per year but <1× per month	83	63.4
≥1× per month	28	21.4
Unknown	6	4.6
GINA control status
Controlled	3	2.3
Partly controlled	11	8.4
Uncontrolled	117	89.3
Systemic steroids/OCS as maintenance medication	72	55.0
Lung function, pre-bronchodilator	Mean (±SD)
FEV1, liter (N=104)	2.70 (±7.44)
FEV1, % (N=105)	65.1 (±24.9)
Eosinophils, cells/μL (N=107)	500 (±438)
Leukocytes, cells/nL (N=108)	8.6 (±2.5)

Note: *Unless otherwise stated.

Abbreviations: GINA, Global Initiative for Asthma; OCS, oral corticosteroids.